Biotech · Private company
Regor Pharmaceuticals Inc.
Track this companyFree. Adds Regor Pharmaceuticals Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials52 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- RGT001-075Phase 2 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- RGT001-075Phase 2 · Obesity or OverweightClinicalTrials.gov · fetched Nov 12, 2026
- RGT001-075Phase 2 · Type 2 Diabetes MellitusClinicalTrials.gov · fetched Nov 12, 2026
- RGT-419BPhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- RGT-419B in combination with hormonal therapyPhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- RGT-490Phase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid TumorsPHASE1 · RECRUITING · started Jul 21, 2026ClinicalTrials.gov NCT07524322 · fetched Nov 12, 2026
- Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health ConditionsPHASE2 · COMPLETED · started Jan 24, 2025ClinicalTrials.gov NCT06867718 · fetched Nov 12, 2026
- A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related ComorbiditiesPHASE2 · COMPLETED · started Mar 8, 2024ClinicalTrials.gov NCT06277934 · fetched Nov 12, 2026
- A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 DiabetesPHASE2 · TERMINATED · started Mar 29, 2022ClinicalTrials.gov NCT05297045 · fetched Nov 12, 2026
- FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast CancerPHASE1 · RECRUITING · started Mar 4, 2022ClinicalTrials.gov NCT05304962 · fetched Nov 12, 2026